Insulin long-acting - Daewoong Pharmaceutical
Latest Information Update: 28 May 2024
At a glance
- Originator Daewoong Pharmaceutical
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 28 May 2024 No recent reports of development identified for preclinical development in Diabetes-mellitus in South Korea (Parenteral)
- 30 Apr 2020 Daewoong exercises development and commercialisation licensing option from Affibody for utilising its Albumod™ technology for development of long-acting insulin
- 28 Dec 2019 No recent reports of development identified for research development in Diabetes mellitus in South Korea